Literature DB >> 10773666

RET rearrangements in papillary thyroid carcinomas and adenomas detected by interphase FISH.

R Cinti1, L Yin, K Ilc, N Berger, F Basolo, S Cuccato, R Giannini, G Torre, P Miccoli, P Amati, G Romeo, R Corvi.   

Abstract

Activation of the RET protooncogene through somatic rearrangements represents the most common genetic alteration in papillary thyroid carcinoma (PTC). Three main rearranged forms of RET have been described: RET/PTC1 and RET/PTC3, which arise from a paracentric inversion of the long arm of chromosome 10, and RET/PTC2, which originates from a 10;17 translocation. We have developed a dual-color FISH approach to detect RET/PTC rearrangements in interphase nuclei of thyroid lesions. By using a pool of three cosmids encompassing the RET chromosome region and a chromosome 10 centromeric probe, we could discriminate between the presence of an inversion (RET/PTC1 and RET/PTC3) or a translocation (RET/PTC2). We have investigated a series of thyroid tissue samples from Italian and French patients corresponding to a total of 69 PTCs and 22 benign lesions. Among PTCs, 13 (18.8%) showed a RET rearrangement, and 11 (15.9%) of these carried an inversion (RET/PTC1 or RET/PTC3) in more than 10% of the nuclei examined. Activated forms of RET were also observed in three adenomas. RT-PCR analysis on the same samples confirmed the presence and the type of rearrangement predicted using FISH analysis. An interesting difference in the frequency and type of RET rearrangements was detected between the Italian and the French patients. Furthermore, we identified a putative novel type of rearrangement in at least one PTC sample. Several PTCs carried a significant number of cells characterized by a trisomy or a tetrasomy of chromosome 10. Overall, the FISH approach in interphase nuclei represents a powerful tool for detecting, at the single cell level, RET/PTC rearrangements and other anomalies involving the RET chromosome region. Copyright 2000 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10773666     DOI: 10.1159/000015485

Source DB:  PubMed          Journal:  Cytogenet Cell Genet        ISSN: 0301-0171


  18 in total

1.  Prevalence of RET/PTC1 and RET/PTC3 gene rearrangements in Chennai population and its correlation with clinical parameters.

Authors:  P Jagan Mohan Rao; N V Vardhini; M V S Parvathi; P Balakrishna Murthy; G Sudhakar
Journal:  Tumour Biol       Date:  2014-06-24

2.  Papillary thyroid carcinoma in a 5-year-old child-case report.

Authors:  B N Gayathri; A Sagayaraj; S Prabhakara; T N Suresh; Merchant Shuaib; S M Azeem Mohiyuddin
Journal:  Indian J Surg Oncol       Date:  2014-03-11

3.  MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo.

Authors:  Ying C Henderson; Yunyun Chen; Mitchell J Frederick; Stephen Y Lai; Gary L Clayman
Journal:  Mol Cancer Ther       Date:  2010-06-29       Impact factor: 6.261

4.  Specific haplotypes of the RET proto-oncogene are over-represented in patients with sporadic papillary thyroid carcinoma.

Authors:  F Lesueur; M Corbex; J D McKay; J Lima; P Soares; P Griseri; J Burgess; I Ceccherini; S Landolfi; M Papotti; A Amorim; D E Goldgar; G Romeo
Journal:  J Med Genet       Date:  2002-04       Impact factor: 6.318

5.  'Chromosomal Rainbows' Detect Oncogenic Rearrangements of Signaling Molecules in Thyroid Tumors.

Authors:  Benjamin O'Brien; Gregg H Jossart; Yuko Ito; Karin M Greulich-Bode; Jingly F Weier; Santiago Munne; Orlo H Clark; Heinz-Ulrich G Weier
Journal:  Open Cell Signal J       Date:  2010

6.  Kinase expression and chromosomal rearrangements in papillary thyroid cancer tissues: investigations at the molecular and microscopic levels.

Authors:  H-U G Weier; J Kwan; C-M Lu; Y Ito; M Wang; A Baumgartner; S W Hayward; J F Weier; H F Zitzelsberger
Journal:  J Physiol Pharmacol       Date:  2009-10       Impact factor: 3.011

7.  RET/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation.

Authors:  Tadao Nakazawa; Shin-ichi Murata; Tetsuo Kondo; Dongfeng Niu; Kunio Mochizuki; Tomonori Kawasaki; Tetsu Yamane; Nobuki Nakamura; Ryohei Katoh
Journal:  Virchows Arch       Date:  2009-06-03       Impact factor: 4.064

8.  ret/PTC activation is not associated with individual radiation dose estimates in a pilot study of neoplastic thyroid nodules arising in Russian children and adults exposed to Chernobyl fallout.

Authors:  R Michael Tuttle; Yvonne Lukes; Lynn Onstad; Eugeni Lushnikov; Alexander Abrosimov; Vladislav Troshin; Anatoli Tsyb; Scott Davis; Kenneth J Kopecky; Gary Francis
Journal:  Thyroid       Date:  2008-08       Impact factor: 6.568

9.  Assessment of RET/PTC oncogene activation and clonality in thyroid nodules with incomplete morphological evidence of papillary carcinoma: a search for the early precursors of papillary cancer.

Authors:  Alfredo Fusco; Gennaro Chiappetta; Pei Hui; Ginesa Garcia-Rostan; Lauren Golden; Barbara K Kinder; Deborah A Dillon; Ada Giuliano; Anna Maria Cirafici; Massimo Santoro; Juan Rosai; Giovanni Tallini
Journal:  Am J Pathol       Date:  2002-06       Impact factor: 4.307

Review 10.  RET/PTC rearrangement in thyroid tumors.

Authors:  Yuri E Nikiforov
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.